Breaking News Instant updates and real-time market news.

2020-12-04 09:03:23 YMAB Y-mAbs Therapeutics $50.76 / -0.07 (-0.14%) , TAK Takeda Pharmaceutical $18.41 / +0.08 (+0.44%) 09:03 12/04/20 12/04 09:03 12/04/20 09:03	Y-mAbs Therapeutics, Takeda announce license, distribution deal for DANYELZA Y-mAbs Therapeutics (YMAB) and Takeda Israel (TAK) announced that they have entered into an exclusive license and distribution agreement for the registration and commercialization in Israel of DANYELZA for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma. DANYELZA was approved by the U.S. FDA on November 25, 2020. Additionally, Y-mAbs plans to resubmit the amended BLA for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma to the FDA by the end of 2020 or in early 2021. Under the terms of the agreement, Takeda will employ its proven platform of sales, access, marketing and regulatory expertise to distribute DANYELZA and omburtamab, if approved, in the territory. The license and distribution agreement includes the State of Israel, West Bank and Gaza Strip. All other geographies worldwide remain with the Company. Financial details were not disclosed. Researchers at MSK developed DANYELZA and omburtamab, which are exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests in the compounds and in Y-mAbs. YMAB Y-mAbs Therapeutics $50.76 / -0.07 (-0.14%) TAK Takeda Pharmaceutical $18.41 / +0.08 (+0.44%)	05 Dec 08 Dec
YMAB TAK YMAB Y-mAbs Therapeutics $50.76 / -0.07 (-0.14%) 11/09/20 Barclays Y-mAbs Therapeutics price target raised to $53 from $47 at Barclays 11/09/20 H.C. Wainwright Y-mAbs Therapeutics price target raised to $65 from $52 at H.C. Wainwright 05/11/20 Wedbush Y-mAbs Therapeutics price target raised to $48 from $41 at Wedbush 05/11/20 H.C. Wainwright Y-mAbs Therapeutics price target raised to $52 from $41 at H.C. Wainwright TAK Takeda Pharmaceutical $18.41 / +0.08 (+0.44%) 06/18/20 RBC Capital Neurocrine price target raised to $135 from $116 at RBC Capital 06/17/20 Oppenheimer Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer 04/20/20 SVB Leerink Ascendis Pharma price target raised to $170 from $152 at SVB Leerink 03/25/20 Piper Sandler Piper Sandler backs Overweight on 'well capitalized' Exelixis

2020-12-04 09:03:23

YMAB

Y-mAbs Therapeutics

$50.76 / -0.07 (-0.14%)

, TAK

Takeda Pharmaceutical

$18.41 / +0.08 (+0.44%)

09:03

12/04/20

12/04

09:03

12/04/20

09:03

Y-mAbs Therapeutics, Takeda announce license, distribution deal for DANYELZA

Y-mAbs Therapeutics (YMAB) and Takeda Israel (TAK) announced that they have entered into an exclusive license and distribution agreement for the registration and commercialization in Israel of DANYELZA for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma. DANYELZA was approved by the U.S. FDA on November 25, 2020. Additionally, Y-mAbs plans to resubmit the amended BLA for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma to the FDA by the end of 2020 or in early 2021. Under the terms of the agreement, Takeda will employ its proven platform of sales, access, marketing and regulatory expertise to distribute DANYELZA and omburtamab, if approved, in the territory. The license and distribution agreement includes the State of Israel, West Bank and Gaza Strip. All other geographies worldwide remain with the Company. Financial details were not disclosed. Researchers at MSK developed DANYELZA and omburtamab, which are exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests in the compounds and in Y-mAbs.

YMAB

Y-mAbs Therapeutics

$50.76 / -0.07 (-0.14%)

TAK

Takeda Pharmaceutical

$18.41 / +0.08 (+0.44%)

05
Dec
08
Dec

YMAB
TAK

YMAB Y-mAbs Therapeutics

$50.76 / -0.07 (-0.14%)

11/09/20 Barclays: Y-mAbs Therapeutics price target raised to $53 from $47 at Barclays

11/09/20 H.C. Wainwright: Y-mAbs Therapeutics price target raised to $65 from $52 at H.C. Wainwright

05/11/20 Wedbush: Y-mAbs Therapeutics price target raised to $48 from $41 at Wedbush

05/11/20 H.C. Wainwright: Y-mAbs Therapeutics price target raised to $52 from $41 at H.C. Wainwright

TAK Takeda Pharmaceutical

$18.41 / +0.08 (+0.44%)

06/18/20 RBC Capital: Neurocrine price target raised to $135 from $116 at RBC Capital

06/17/20 Oppenheimer: Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer

04/20/20 SVB Leerink: Ascendis Pharma price target raised to $170 from $152 at SVB Leerink

03/25/20 Piper Sandler: Piper Sandler backs Overweight on 'well capitalized' Exelixis

TODAY'S FREE FLY STORIES

Recommendations	Chr. Hansen price target lowered to DKK 470 from DKK 484 at Barclays » 13:29 01/15/21 01/15 13:29 01/15/21 13:29 CHYHY Chr. Hansen $0.00 / + (+0.00%) Barclays analyst Alex… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research CHYHY Chr. Hansen $0.00 / + (+0.00%) 05:14 Today DNB Markets Chr. Hansen upgraded to Hold from Sell at DNB Markets 01/07/21 Danske Bank Chr. Hansen upgraded to Buy from Hold at Danske Bank 12/03/20 JPMorgan Chr. Hansen price target raised to DKK 500 from DKK 495 at JPMorgan 12/01/20 UBS Chr. Hansen price target lowered to DKK 650 from DKK 700 at UBS
General news	Wall Street remains weaker » 13:25 01/15/21 01/15 13:25 01/15/21 13:25 Wall Street remains… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Options	BioCryst call volume above normal and directionally bullish » 13:25 01/15/21 01/15 13:25 01/15/21 13:25 BCRX BioCryst $8.81 / +0.21 (+2.44%) Bullish option flow… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options BCRX BioCryst $8.81 / +0.21 (+2.44%) 01/07/21 BioCryst reports inducement grants under Nasdaq listing rule 12/22/20 BioCryst expects NIAID to stop Covid indication for galidesivir 12/22/20 BioCryst says data shows galidesivir was safe, generally well tolerated 12/16/20 BioCryst announces U.S. availability of ORLADEYO for hereditary angioedema BCRX BioCryst $8.81 / +0.21 (+2.44%) 12/22/20 JMP Securities BioCryst selloff today a buying opportunity, says JMP Securities 12/07/20 H.C. Wainwright BioCryst price target raised to $14 from $13 at H.C. Wainwright 12/04/20 Piper Sandler BioCryst receives on-time approval with 'clean' label, says Piper Sandler 11/23/20 Evercore ISI BioCryst initiated with an Outperform at Evercore ISI BCRX BioCryst $8.81 / +0.21 (+2.44%) 11/05/20 BioCryst reports Q3 EPS (26c), consensus (25c) 08/06/20 BioCryst reports Q2 EPS (24c), consensus (25c) 28 May BCRX BioCryst $8.81 / +0.21 (+2.44%) 12/04/20 Fly Intel: Pre-market Movers 10/22/20 Fly Intel: Pre-market Movers 09/30/20 Fly Intel: Wall Street's top stories for Wednesday 09/30/20 Fly Intel: Wall Street's top stories at midday BCRX BioCryst $8.81 / +0.21 (+2.44%) 12/04/20 Unusually active option classes on open December 4th 07/16/20 BioCryst call volume above normal and directionally bullish
General news	Oil Action: The weekly Baker Hughes oil rig count » 13:25 01/15/21 01/15 13:25 01/15/21 13:25 Oil Action: The weekly… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Technical Analysis	NASDAQ market internals summary » 13:17 01/15/21 01/15 13:17 01/15/21 13:17 $NSD NASDAQ Market Internals $0.00 / + (+0.00%) Volume is above average… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Technical Analysis $NSD NASDAQ Market Internals $0.00 / + (+0.00%) 12:17 Today NASDAQ market internals summary 11:17 Today NASDAQ market internals summary 10:17 Today NASDAQ market internals summary 01/14/21 NASDAQ market internals summary

Technical Analysis	NYSE market internals summary » 13:16 01/15/21 01/15 13:16 01/15/21 13:16 $NYE NYSE Market Internals $0.00 / + (+0.00%) Volume is above average… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Technical Analysis $NYE NYSE Market Internals $0.00 / + (+0.00%) 12:16 Today NYSE market internals summary 11:16 Today NYSE market internals summary 10:16 Today NYSE market internals summary 01/14/21 NYSE market internals summary
Hot Stocks	Baker Hughes reports U.S. rig count up 13 to 373 rigs » 13:11 01/15/21 01/15 13:11 01/15/21 13:11 BKR Baker Hughes $22.95 / -0.77 (-3.25%) Baker Hughes reports that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events BKR Baker Hughes $22.95 / -0.77 (-3.25%) 13:01 Today Baker Hughes reports U.S. rig count up 13 to 373 rigs 01/08/21 Baker Hughes reports U.S. rig count up 9 to 360 rigs 01/08/21 Baker Hughes reports U.S. rig count up 9 to 360 rigs 12/30/20 Baker Hughes reports U.S. rig count up 3 to 351 rigs BKR Baker Hughes $22.95 / -0.77 (-3.25%) 01/13/21 JPMorgan JPMorgan announces top 10 energy picks for 2021 01/08/21 Barclays Baker Hughes downgraded to Equal Weight from Overweight at Barclays 12/18/20 JPMorgan Baker Hughes price target raised to $23 from $20 at JPMorgan 12/15/20 Citi Baker Hughes downgraded to Neutral from Buy at Citi BKR Baker Hughes $22.95 / -0.77 (-3.25%) 10/21/20 Baker Hughes reports Q3 EPS 4c, consensus 4c 10/20/20 Notable companies reporting before tomorrow's open 10/20/20 Notable companies reporting before tomorrow's open 07/22/20 Baker Hughes reports Q2 adj. EPS (5c), consensus 0c BKR Baker Hughes $22.95 / -0.77 (-3.25%) 11/11/20 OPEC+ discussing possible 3-to-6 month delay of production hikes, Bloomberg says BKR Baker Hughes $22.95 / -0.77 (-3.25%) 10/21/20 Fly Intel: Pre-market Movers 01/21/21 Baker Hughes - BKR
Recommendations	Geberit price target lowered to CHF 475 from CHF 479 at Morgan Stanley » 13:10 01/15/21 01/15 13:10 01/15/21 13:10 GBERY Geberit $0.00 / + (+0.00%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research GBERY Geberit $0.00 / + (+0.00%) 01/13/21 Berenberg Geberit price target raised to CHF 545 from CHF 460 at Berenberg 01/07/21 Morgan Stanley Geberit price target raised to CHF 479 from CHF 477 at Morgan Stanley 11/11/20 UBS Geberit price target raised to CHF 550 from CHF 435 at UBS 10/30/20 Barclays Geberit price target raised to CHF 485 from CHF 470 at Barclays
Recommendations	Vestas price target raised to DKK 1,099 from DKK 1,066 at Morgan Stanley » 13:09 01/15/21 01/15 13:09 01/15/21 13:09 VWDRY Vestas $0.00 / + (+0.00%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research VWDRY Vestas $0.00 / + (+0.00%) 01/12/21 Deutsche Bank Vestas price target raised to DKK 1630 from DKK 1350 at Deutsche Bank 01/08/21 Citi Vestas price target raised to DKK 1,850 at Citi 01/04/21 Danske Bank Vestas downgraded to Hold from Buy at Danske Bank 12/09/20 Deutsche Bank Vestas price target raised to DKK 1,350 from DKK 1,260 at Deutsche Bank
Recommendations	Siemens Energy price target raised to EUR 33 from EUR 29 at Morgan Stanley » 13:09 01/15/21 01/15 13:09 01/15/21 13:09 SMEGF Siemens Energy $0.00 / + (+0.00%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research SMEGF Siemens Energy $0.00 / + (+0.00%) 01/12/21 Deutsche Bank Siemens Energy price target raised to EUR 35 from EUR 30 at Deutsche Bank 12/09/20 Deutsche Bank Siemens Energy price target raised to EUR 30 from EUR 27 at Deutsche Bank 12/07/20 JPMorgan Siemens Energy price target raised to EUR 28 from EUR 26 at JPMorgan 11/12/20 Berenberg Siemens Energy price target raised to EUR 29 from EUR 28 at Berenberg

Recommendations	Prysmian price target raised to EUR 30 from EUR 29 at Morgan Stanley » 13:08 01/15/21 01/15 13:08 01/15/21 13:08 PRYMY Prysmian $0.00 / + (+0.00%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research PRYMY Prysmian $0.00 / + (+0.00%) 01/07/21 Citi Prysmian price target raised to EUR 34 from EUR 33 at Citi 12/09/20 Citi Prysmian initiated with a Buy at Citi 12/08/20 Morgan Stanley Prysmian price target raised to EUR 29 from EUR 27 at Morgan Stanley 10/30/20 Morgan Stanley Prysmian price target lowered to EUR 27 from EUR 28 at Morgan Stanley
Recommendations	Metso Outotec price target raised to EUR 9.30 from EUR 7.30 at Morgan Stanley » 13:07 01/15/21 01/15 13:07 01/15/21 13:07 OUKPY Metso Outotec $0.00 / + (+0.00%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research OUKPY Metso Outotec $0.00 / + (+0.00%) 12/07/20 JPMorgan Metso Outotec price target raised to EUR 8.50 from EUR 8 at JPMorgan 10/30/20 Morgan Stanley Metso Outotec upgraded to Overweight from Equal Weight at Morgan Stanley 10/12/20 Credit Suisse Metso Outotec initiated with an Outperform at Credit Suisse 09/28/20 Societe Generale Metso Outotec initiated with a Buy at Societe Generale
Conference/Events	Green Plains participates in a conference call with Truist » 13:06 01/15/21 01/15 13:06 01/15/21 13:06 GPRE Green Plains $17.82 / -0.59 (-3.20%) Conference call to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events GPRE Green Plains $17.82 / -0.59 (-3.20%) 01/12/21 Green Plains completes York USP upgrade 01/05/21 Green Plains, Ospraie Management to acquire majority stake in Fluid Quip 12/15/20 Green Plains enters into agreement to sell Hereford plant 10/27/20 Green Plains and Hayashikane form 'exclusive' partnership GPRE Green Plains $17.82 / -0.59 (-3.20%) 01/06/21 Roth Capital Green Plains price target raised to $20 from $11 at Roth Capital 10/19/20 Fly Intel: Top five analyst initiations 10/19/20 Truist Green Plains initiated with a Buy at Truist 08/05/20 Craig-Hallum Green Plains price target raised to $18 from $11 at Craig-Hallum GPRE Green Plains $17.82 / -0.59 (-3.20%) 11/04/20 Green Plains reports Q3 EPS ($1.00), consensus (28c) 08/03/20 Green Plains reports Q2 EPS (24c), consensus (70c) 03/15/21 33rd Annual Roth Virtual Conference 01/19/21 Green Plains - GPRE
Recommendations	Melrose price target raised to 148 GBp from 140 GBp at Morgan Stanley » 13:06 01/15/21 01/15 13:06 01/15/21 13:06 MLSPF Melrose Industries $0.00 / + (+0.00%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research MLSPF Melrose Industries $0.00 / + (+0.00%) 11/30/20 UBS Melrose Industries price target raised to 185 GBp from 134 GBp at UBS 11/26/20 Stifel Melrose Industries downgraded to Hold from Buy at Stifel 10/02/20 Panmure Gordon Melrose Industries downgraded to Sell from Hold at Panmure Gordon 09/04/20 Stifel Melrose Industries price target raised to 135 GBp from 125 GBp at Stifel
Recommendations	Kion Group price target raised to EUR 68 from EUR 64 at Morgan Stanley » 13:05 01/15/21 01/15 13:05 01/15/21 13:05 KIGRY Kion Group / + Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research KIGRY Kion Group / + 01/12/21 Deutsche Bank Kion Group price target raised to EUR 75 from EUR 70 at Deutsche Bank 12/08/20 Berenberg Kion Group price target lowered to EUR 81 from EUR 86 at Berenberg 12/07/20 Deutsche Bank Kion Group price target lowered to EUR 70 from EUR 78 at Deutsche Bank 12/02/20 HSBC Kion Group upgraded to Buy from Hold at HSBC

Recommendations	GEA Group price target raised to EUR 29 from EUR 28 at Morgan Stanley » 13:05 01/15/21 01/15 13:05 01/15/21 13:05 GEAGY GEA Group / + Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research GEAGY GEA Group / + 01/12/21 Deutsche Bank GEA Group price target raised to EUR 27 from EUR 26 at Deutsche Bank 12/07/20 Deutsche Bank GEA Group upgraded to Hold from Sell at Deutsche Bank 11/09/20 JPMorgan GEA Group price target raised to EUR 23 from EUR 21.50 at JPMorgan 10/22/20 Barclays GEA Group price target raised to EUR 34 from EUR 33 at Barclays
Recommendations	IMI PLC price target raised to 1,400 GBp from 1,320 GBp at Morgan Stanley » 13:05 01/15/21 01/15 13:05 01/15/21 13:05 IMIAY IMI PLC $0.00 / + (+0.00%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research IMIAY IMI PLC $0.00 / + (+0.00%) 01/13/21 Credit Suisse IMI PLC upgraded to Outperform at Credit Suisse on guidance upside 01/13/21 Credit Suisse IMI PLC upgraded to Outperform from Neutral at Credit Suisse 12/01/20 Exane BNP Paribas IMI PLC downgraded to Neutral from Outperform at Exane BNP Paribas 11/24/20 JPMorgan IMI PLC upgraded to Overweight from Neutral at JPMorgan
Options	Eli Lilly call volume above normal and directionally bullish » 13:05 01/15/21 01/15 13:05 01/15/21 13:05 LLY Eli Lilly $191.20 / +4.42 (+2.37%) Bullish option flow… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options LLY Eli Lilly $191.20 / +4.42 (+2.37%) 09:27 Today Eli Lilly reports $30M limited partner investment in Unseen Capital Health Fund 01/11/21 Eli Lilly rises 12.5% 01/11/21 AC Immune, Biogen rise after Lilly reports Alzheimer's study met endpoint 01/11/21 Eli Lilly rises 11.0% LLY Eli Lilly $191.20 / +4.42 (+2.37%) 01/12/21 Truist Eli Lilly price target raised to $200 from $182 at Truist 01/11/21 JPMorgan Alzheimer's data a 'significant positive' for Eli Lilly story, says JPMorgan 01/11/21 Goldman Sachs Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs 01/07/21 KeyBanc Veeva initiated with an Overweight at KeyBanc LLY Eli Lilly $191.20 / +4.42 (+2.37%) 12/15/20 Eli Lilly sees FY21 EPS $7.75-$8.40, consensus $8.07 12/15/20 Eli Lilly raises FY20 EPS view to $7.45-$7.65 from $7.20-$7.40, consensus $7.32 12/02/20 Eli Lilly says updated purchase of LY-CoV555 to boost FY20 EPS view by 25c 10/27/20 Eli Lilly backs FY20 adj. EPS view $7.20-$7.40, consensus $7.28 LLY Eli Lilly $191.20 / +4.42 (+2.37%) 12/30/20 Fresenius to administer Lilly, Regeneron COVID antibody drugs, Reuters says 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports LLY Eli Lilly $191.20 / +4.42 (+2.37%) 01/11/21 Fly Intel: Wall Street's top stories for Monday 01/11/21 Fly Intel: Wall Street's top stories at midday 01/11/21 Eli Lilly and Alzheimer's research peers jump after study meets endpoint 01/11/21 Fly Intel: Pre-market Movers 01/26/21 Pharmacovigilance & Risk Management Strategies Virtual Conference 01/28/21 IASLC Virtual World Conference on Lung Cancer 01/29/21 Eli Lilly - LLY LLY Eli Lilly $191.20 / +4.42 (+2.37%) 01/13/21 Early notable gainers among liquid option names on January 13th 01/11/21 Early notable gainers among liquid option names on January 11th 12/09/20 Early notable gainers among liquid option names on December 9th 12/09/20 Unusually active option classes on open December 9th
Recommendations	Epiroc price target raised to SEK 132 from SEK 122 at Morgan Stanley » 13:04 01/15/21 01/15 13:04 01/15/21 13:04 EPOKY Epiroc $0.00 / + (+0.00%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research EPOKY Epiroc $0.00 / + (+0.00%) 12/22/20 Dundee Precious Metals announces sale of MineRP to Epiroc Canada EPOKY Epiroc $0.00 / + (+0.00%) 01/13/21 Barclays Epiroc price target raised to SEK 160 from SEK 142 at Barclays 01/12/21 Deutsche Bank Epiroc price target raised to SEK 140 from SEK 130 at Deutsche Bank 12/07/20 JPMorgan Epiroc price target raised to SEK 135 from SEK 125 at JPMorgan 11/02/20 RBC Capital Epiroc price target raised to SEK 125 from SEK 120 at RBC Capital
Recommendations	Electrolux price target raised to SEK 40 from SEK 37 at Morgan Stanley » 13:03 01/15/21 01/15 13:03 01/15/21 13:03 ELUXY Electrolux $0.00 / + (+0.00%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research ELUXY Electrolux $0.00 / + (+0.00%) 01/06/21 Morgan Stanley Electrolux price target lowered to SEK 205 from SEK 215 at Morgan Stanley 12/21/20 Pareto Electrolux downgraded to Hold from Buy at Pareto 12/01/20 Exane BNP Paribas Electrolux downgraded to Neutral from Outperform at Exane BNP Paribas 11/05/20 Morgan Stanley Electrolux price target raised to SEK 215 from SEK 181 at Morgan Stanley

Hot Stocks	Northern Technologies reinstates quarterly dividend of 6.5c per share » 13:03 01/15/21 01/15 13:03 01/15/21 13:03 NTIC Northern Technologies $12.69 / -0.23 (-1.78%) Northern Technologies… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Earnings Events NTIC Northern Technologies $12.69 / -0.23 (-1.78%) 11/13/20 Northland Northern Technologies price target raised to $15 from $13 at Northland NTIC Northern Technologies $12.69 / -0.23 (-1.78%) 01/07/21 Northern Technologies reports Q1 EPS 13c, one est. 5c 11/12/20 Northern Technologies reports Q4 EPS (15c), one est. (5c) 12:00 Today Northern Technologies International Co.
Recommendations	Duerr price target raised to EUR 36 from EUR 33 at Morgan Stanley » 13:03 01/15/21 01/15 13:03 01/15/21 13:03 DURYY Duerr $0.00 / + (+0.00%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research DURYY Duerr $0.00 / + (+0.00%) 05/14/20 Commerzbank Duerr downgraded to Hold from Buy at Commerzbank
Recommendations	Continental AG price target raised to EUR 125 from EUR 105 at Morgan Stanley » 13:02 01/15/21 01/15 13:02 01/15/21 13:02 CTTAY Continental AG $0.00 / + (+0.00%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals CTTAY Continental AG $0.00 / + (+0.00%) 11/12/20 Continental AG names Nikolai Setzer as Executive Board chairman CTTAY Continental AG $0.00 / + (+0.00%) 01/07/21 Deutsche Bank Continental AG price target raised to EUR 120 from EUR 100 at Deutsche Bank 01/05/21 JPMorgan Continental AG upgraded to Overweight from Neutral at JPMorgan 01/04/21 JPMorgan Continental AG upgraded to Overweight from Neutral at JPMorgan 11/24/20 Citi Continental AG upgraded to Buy from Neutral at Citi CTTAY Continental AG $0.00 / + (+0.00%) 10/21/20 Continental AG reports preliminary Q3 consolidated sales of EUR 10.3B 07/20/20 Continental AG reports preliminary Q2 consolidated sales EUR6.62B CTTAY Continental AG $0.00 / + (+0.00%) 10/29/20 Continental AG may replace CEO with head of auto unit, Bloomberg says
Recommendations	Bouygues price target raised to EUR 45 from EUR 42 at Morgan Stanley » 13:01 01/15/21 01/15 13:01 01/15/21 13:01 BOUYF Bouygues $0.00 / + (+0.00%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research BOUYF Bouygues $0.00 / + (+0.00%) 01/13/21 JPMorgan Bouygues price target raised to EUR 44 from EUR 43 at JPMorgan 01/13/21 Barclays Bouygues price target raised to EUR 36.50 from EUR 36 at Barclays 12/08/20 JPMorgan Bouygues price target raised to EUR 43 from EUR 41 at JPMorgan 10/21/20 Morgan Stanley Bouygues price target lowered to EUR 42 from EUR 43 at Morgan Stanley
Recommendations	Banco Santander price target raised to EUR 3.50 from EUR 3.30 at Morgan Stanley » 13:01 01/15/21 01/15 13:01 01/15/21 13:01 SAN Banco Santander $3.30 / -0.135 (-3.94%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options SAN Banco Santander $3.30 / -0.135 (-3.94%) 12/15/20 ECB asks banks to refrain from or limit dividends until September 2021 12/15/20 ECB asks banks to refrain from or limit dividends until September 2021 11/16/20 Santander agrees to acquire technology assets from Wirecard 07/31/20 SHUSA's request approved for certain exceptions to FRB interim policy SAN Banco Santander $3.30 / -0.135 (-3.94%) 01/11/21 Deutsche Bank Banco Santander price target raised to EUR 2.85 from EUR 2.80 at Deutsche Bank 01/11/21 UBS Banco Santander upgraded to Buy from Neutral at UBS 12/14/20 JPMorgan Banco Santander price target raised to EUR 2.50 from EUR 2.30 at JPMorgan 12/08/20 Morgan Stanley Banco Santander price target raised to EUR 3.30 from EUR 3 at Morgan Stanley SAN Banco Santander $3.30 / -0.135 (-3.94%) 10/30/20 Santander Chile reports Q3 EPS 28c, consensus 26c SAN Banco Santander $3.30 / -0.135 (-3.94%) 11/13/20 Santander plans to cut 4,000 positions, Reuters reports SAN Banco Santander $3.30 / -0.135 (-3.94%) 11/16/20 Fly Intel: Wall Street's top stories for Monday 09/11/20 The Intersection: Crypto and Wall Street This Week SAN Banco Santander $3.30 / -0.135 (-3.94%) 12/21/20 Unusually active option classes on open December 21st 09/22/20 Largest borrow rate increases among liquid names 09/21/20 Largest borrow rate increases among liquid names 09/18/20 Largest borrow rate increases among liquid names

Events

Earnings calls, analyst events, roadshows and more

FPRX
Today at 16:30

Five Prime - FPRX Conference Calls
ZYME
Today at 17:00

Zymeworks - ZYME Conference Calls
MDT ...
Tomorrow at 00:00

2021 NANS Virtual Meeting Conferences

Virtual Meeting
Tomorrow at 00:00

ASCO-GI: Gastrointestinal Cancers Virtual Symposium Conferences

Virtual Symposium
HDB
Tomorrow at 06:30

HDFC Bank - HDB Conference Calls
2021-01-17 at 00:00

ASCO-GI: Gastrointestinal Cancers Virtual Symposium Conferences

Virtual Symposium
2021-01-18 at 00:00

Thailand C-Suite Virtual Corporate Day Conferences

Virtual Conference
LUMO
2021-01-18 at 00:00

Lumos Pharma Firm Sponsored Meetings

Virtual Meeting
2021-01-18 at 00:00

Biotechnology Industry Meetings

Virtual Meeting
CEI
2021-01-18 at 11:00

Camber Energy, Inc. Firm Sponsored Meetings

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	QLI X QLI Qilian International IPO Managers: Univest Securities, Loop Capital & Alexander Capital Priced at: $5.00 5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDGS X MDGS Medigus Secondary Managers: Aegis Priced at: $2.30 3.66M Shares O X O Realty Income Spot Secondary Managers: BofA, Morgan Stanley, Wells Fargo & Citi Priced at: $57.05 10.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PSTL X PSTL Postal Realty Trust Spot Secondary Managers: Jefferies, Stifel, BMO Capital & Janney Montgomery Scott Priced at: $15.25 3.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	ALXO X ALXO ALX Oncology Block Trade Managers: Jefferies Priced at: $82.00 250K Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial IMAB X IMAB I-MAB Block Trade Managers: Jefferies Priced at: $53.00 642K Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AFRM X AFRM Affirm IPO Managers: Morgan Stanley, Goldman Sachs & Allen & Co., RBC Capital, Credit Suisse, Barclays, Truist, SIEB, Deutsche Bank Priced at: $49.00 24.6M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MSGM X MSGM Motorsport Games IPO Managers: Canaccord & Benchmark Priced at: $20.00 3M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HCDI X HCDI Harbor Custom Development Secondary Managers: ThinkEquity Priced at: $3.00 8M Shares ZM X ZM Zoom Video Secondary Managers: JPMorgan Priced at: $340.00 5.1M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AFMD X AFMD Affimed N.V. Spot Secondary Managers: Jefferies, SVB Leerink & Credit Suisse Priced at: $6.00 16.667M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RILY X RILY B. Riley Financial Spot Secondary Managers: B. Riley Securities Priced at: $46.00 1.229M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	POSH X POSH Poshmark IPO Managers: Morgan Stanley, Goldman Sachs & Barclays, Stifel, William Blair, Raymond James, Cowen, JMP Securities Priced at: $42.00 6.6M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial WOOF X WOOF Petco IPO Managers: Goldman Sachs & BofA, Citi, Evercore ISI, Credit Suisse, UBS, Wells Fargo, Baird, Guggenheim, AmeriVet, CL King, R. Seelaus, Ramirez, SIEB Priced at: $18.00 48M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LMND X LMND Lemonade Secondary Managers: Goldman Sachs, Morgan Stanley, Allen & Co. & Barclays Priced at: $165.00 4.524M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PRVB X PRVB Provention Bio Secondary Managers: SVB Leerink & Cantor Fitzgerald Priced at: $16.00 6.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RPAY X RPAY Repay Holdings Secondary Managers: Credit Suisse & Barclays, Citi, Truist Priced at: $24.00 5.43M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VNT X VNT Vontier Secondary Managers: Goldman Sachs, Citi & Evercore ISI, JPMorgan, Morgan Stanley, Credit Suisse, UBS, Baird Priced at: $33.50 33.507M Shares ALDX X ALDX Aldeyra Spot Secondary Managers: Jefferies & SVB Leerink Priced at: $9.50 6.842M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EVOK X EVOK Evoke Pharma Spot Secondary Managers: Laidlaw Priced at: $2.50 5M Shares
Thurs	DRVN X DRVN Driven Brands IPO Managers: Morgan Stanley, BofA, Goldman Sachs, JPMorgan & Barclays, Credit Suisse, Baird, Piper Sandler, William Blair Priced at: $22.00 31.8M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KUKE X KUKE Kuke Music IPO Managers: Deutsche Bank, Tigress Financial, AMTD & China International, Valuable Capital Priced at: $10.00 5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PLTK X PLTK Playtika IPO Managers: Morgan Stanley, Credit Suisse, Citi, Goldman Sachs, UBS & BofA, Baird, Cowen, Stifel, Wedbush Priced at: $27.00 69.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AMWL X AMWL Amwell Secondary Managers: Morgan Stanley, Goldman Sachs, Piper Sandler & UBS, Credit Suisse, Cowen, Berenberg Priced at: $27.50 11.281M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ITP X ITP IT Tech Packaging Secondary Managers: Maxim Priced at: $.55 26.182M Shares EAF X EAF GrafTech Spot Secondary Managers: Morgan Stanley Priced at: $10.90 20M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LTRN X LTRN Lantern Pharma Spot Secondary Managers: ThinkEquity Priced at: $14.00 4.28M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

View All Syndicate Announcements »

Y-mAbs Therapeutics, Takeda announce license, distribution deal for DANYELZA

TODAY'S FREE FLY STORIES

Get Full Fly Access